intellectual property
Editas Medicine Raises $57M by Selling Future Payments From CRISPR Licensing Deal With Vertex Pharma
Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and payments it is owed under an earlier deal with Vertex.
Lexeo, Weill Cornell Data Rights Pact to Speed Development of FA Cardiomyopathy Gene Therapy
The firm has in-licensed data rights on LX2006 that will allow it to double the number of evaluable patients in clinical trials.
Taysha Gene Therapies Transfers IP for Five Programs to Extend Cash Runway Into 2026
The firm has transferred rights to collaborators and originating institutions for the programs as it focuses on its lead candidate for Rett syndrome.
Editas Medicine, Vertex Strike Nonexclusive License Deal on Cas9 Gene Editing Technology
For $50 million upfront and contingent payments, Vertex can use Editas' Cas9 gene editing technology to make sickle cell disease and beta thalassemia gene therapies, including Casgevy.
Hong Kong Startup Licenses Nasopharyngeal Cancer Early Detection Technology From Grail
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.